Sang-Hoon Kim
Präsident bei BUKWANG PHARMACEUTICAL CO., LTD.
Vermögen: 2 Mio $ am 31.05.2024
Aktive Positionen von Sang-Hoon Kim
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
BUKWANG PHARMACEUTICAL CO., LTD. | Direktor/Vorstandsmitglied | 02.03.2010 | - |
Präsident | 15.03.2013 | - | |
Vorstandsvorsitzender | 15.03.2013 | - | |
Corporate Officer/Principal | 02.03.2010 | 27.06.2014 | |
Contera Pharma ApS
Contera Pharma ApS Pharmaceuticals: MajorHealth Technology Contera Pharma ApS is a holding company that identifies and develops treatments for patients suffering from movement disorders. It develops drug candidates based on a combination of repositioning, combinations, and reformulations. The firm's lead project JM-010 is for treatment of dyskinesia associated with Parkinson's disease. It develops an approach of using a combination therapy to tackle clinically relevant synergistic pathways to obtain therapeutic effects which will generate efficacious therapeutic entities based on robust pre-clinical and clinical evidence. The company was founded by Mikael Søndergaard Thomsen and John Bondo Hansen in 2010 and is headquartered in Copenhagen, Denmark. | Direktor/Vorstandsmitglied | - | - |
Dyna Therapeutics Co., Ltd. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Sang-Hoon Kim
Ausbildung von Sang-Hoon Kim
Boston University | Undergraduate Degree |
Statistik
International
Südkorea | 3 |
Israel | 2 |
Dänemark | 2 |
Operativ
Director/Board Member | 3 |
Chief Executive Officer | 1 |
Corporate Officer/Principal | 1 |
Sektoral
Health Technology | 3 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
BUKWANG PHARMACEUTICAL CO., LTD. | Health Technology |
Private Unternehmen | 2 |
---|---|
Contera Pharma ApS
Contera Pharma ApS Pharmaceuticals: MajorHealth Technology Contera Pharma ApS is a holding company that identifies and develops treatments for patients suffering from movement disorders. It develops drug candidates based on a combination of repositioning, combinations, and reformulations. The firm's lead project JM-010 is for treatment of dyskinesia associated with Parkinson's disease. It develops an approach of using a combination therapy to tackle clinically relevant synergistic pathways to obtain therapeutic effects which will generate efficacious therapeutic entities based on robust pre-clinical and clinical evidence. The company was founded by Mikael Søndergaard Thomsen and John Bondo Hansen in 2010 and is headquartered in Copenhagen, Denmark. | Health Technology |
Dyna Therapeutics Co., Ltd. |
- Börse
- Insiders
- Sang-Hoon Kim
- Erfahrung